Renaissance Technologies’s Jasper Therapeutics JSPR Stock Holding History

Renaissance Technologies’s Portfolio JSPR Stock Details JSPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$156K	Sell	177,500 -49,683	-22%	-$69K	﹤0.01%	2958
2025 Q4	$416K	Buy	227,183 +18,683	+9%	+$37.5K	﹤0.01%	2643
2025 Q3	$496K	Buy	208,500 +198,100	+1,905%	+$601K	﹤0.01%	2794
2025 Q2	$57.7K	Buy	+10,400	New	+$51.2K	﹤0.01%	3373
2024 Q1	–	Sell	-51,432	Closed	-$406K	–	3898
2023 Q4	$406K	Buy	51,432 +20,411	+66%	+$137K	﹤0.01%	2868
2023 Q3	$217K	Buy	31,021 +25,211	+434%	+$308K	﹤0.01%	3063
2023 Q2	$80K	Sell	5,810 -5,210	-47%	-$77.4K	﹤0.01%	3519
2023 Q1	$199K	Buy	11,020 +4,480	+69%	+$82.8K	﹤0.01%	3286
2022 Q4	$32K	Buy	6,540 +3,680	+129%	+$24.6K	﹤0.01%	3876
2022 Q3	$23K	Buy	+2,860	New	+$52.3K	﹤0.01%	3880
2022 Q2	–	Sell	-1,087	Closed	-$39K	–	4412
2022 Q1	$39K	Buy	+1,087	New	+$49K	﹤0.01%	3940

Other funds holding JSPR

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

LPC

Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

Renaissance Technologies's JSPR Position: Q1 2026 in Review

Renaissance Technologies reduced its Jasper Therapeutics (JSPR) stake by 22% in Q1 2026, selling an estimated $69K and leaving 177,500 shares worth $156K. The position accounts for ﹤0.01% of the portfolio, ranked #2958.

Renaissance Technologies first reported a position in JSPR in Q1 2022 and has held it in 11 quarters since. The position peaked at $496K in Q3 2025. 58 funds tracked by Wall St. Rank hold JSPR as of Q1 2026.

Renaissance Technologies held 177,500 shares of Jasper Therapeutics worth $156K as of Q1 2026.
Renaissance Technologies sold 49,683 Jasper Therapeutics shares in Q1 2026, an estimated $69K.
Jasper Therapeutics made up ﹤0.01% of Renaissance Technologies's portfolio in Q1 2026, its #2958 holding.
Renaissance Technologies first reported a position in Jasper Therapeutics in Q1 2022 and has held it in 11 quarters since.
Renaissance Technologies's Jasper Therapeutics position peaked at $496K in Q3 2025.
58 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.